Ok Fellas, I AM IN THE MONEYYYYYYY. I am well in the green on the shorts and will cover and go long soon. I will let you know so you can actually follow and make money this time around. Giggle Giggle
Traders always make more money in today's market. Hey, but I don't mind taking your money every cycle. Giggle Giggle
GHDX was just upgraded by UA (underground stock alerts- google them ) to a BUY with a new price target of 43 that’s HUGE. i’m subscribed to UA’s free newsletter, their subscriber base is huge, the last time they alerted a buy the stock ended up going up 1350% in a very short period, no way this will happen with GHDX but it’s still very positive. i’ve made over $200k with their free alerts so far so it’s definitely not something to sneeze at.
Actually, just for fun I have looked at your other posts. You are an almost pathological liar. But to prevent you from getting your pay for these posts, I will no longer respond.
Thoughts anybody on FMI's recent IPO and the impact that FMI will have in this increasingly crowded space?
While GHDX is the clear leader in the specific genomic tests for breast, colon and prostate cancer - to guide treatment decisions, the new competitor on the block is FMI. Looks like they could eat GHDX's lunch.
I'm currently in a HOLD pattern with GHDX, but I'm aware that they could potentially lose their leadership position. Your thoughts, Terry?
sblum2000, I told you the entire time my positions and when I bought and sold. Loss money on the last trade her due to several PUMPERTURDS who led us all the BUY BUY banner as always. I am short here now and only up on my shorts .08 so that should make you feel better. I have never lied to you but I can not say the same for your other posters. Giggle Giggle
Genomic Health, Inc. : NICE Recommends Genomic Health's Oncotype DX® Test To Guide Chemotherapy Treatment Decisions For Qualified Early-Stage Invasive Breast Cancer Patients
09/25/2013 | 05:31am US/EasternRecommend:
REDWOOD CITY, Calif., Sept. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX(®) as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients with early-stage, hormone receptor-positive, invasive breast cancer. Consistent with leading international breast cancer treatment guidelines, including ASCO(®), NCCN(®), ESMO(®) and St. Gallen, NICE's recommendation recognizes the unparalleled evidence of the clinical validity of the Oncotype DX test and its ability to enable physicians and their patients to make more informed, individualized decisions.
"It is encouraging to see growing recognition of the value of genomic testing. Its provision has enhanced the care of breast cancer patients around the world and it will now be available as an option in the UK," said David Miles, M.D., medical oncologist at Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. "NICE's recommendation for the use of Oncotype DX in the UK is an important step forward, enabling physicians and patients to make better-informed treatment decisions based on the biology of an individual patient's breast cancer."
To date, more than 1,500 women in the UK have utilized the Oncotype DX test to help guide their treatment decisions. Breast cancer is the most commonly diagnosed cancer in women, with almost 50,000 people diagnosed each year in the UK. Most of these patients are diagnosed with early-stage, invasive breast cancer and a significant number of them could benefit from this test under the NIC
No, no, you have your scripts mixed up. This is where you tell us you had a simultaneous short position that you just closed out for a profit. This is not a bad place to pick up some shares of GHDX. Ray James is underestimating performance and price increases.
You guys have let me down. Terry was pumping on other boards how great this stock was and now lose money here too. Sold yesterday for a loss. I guess Pumperturds will always be pumperturds.
Ray James downgrade is the official word..Those impatient investors hate these yearly doubles.tested 200 day today with a bottoming tail.